Mike’s Story

Mike*


  • 72-year-old retired engineer
  • Prior radical prostatectomy
  • Received ADT for 24 months following biological recurrence
  • Is now castrate-resistant
  • Recently diagnosed with metastatic disease
  • Is asymptomatic and does not require narcotics for cancer pain
Mike is part of the 87%

*Not an actual patient.

Mike represents one of the 87%…and may be a candidate for early treatment with PROVENGE to fight his metastatic castrate-resistant prostate cancer1

A routine scan uncovered Mike’s metastatic castrate-resistant prostate cancer early

Spine Scan

Metastatic disease may not be discovered without proactive imaging2†

Over 30% of men thought to have nonmetastatic CRPC were found to have metastatic disease when screened via imaging2†

  • Most men with CRPC will eventually develop metastatic disease3,4
  • Patients with confirmed metastatic disease revealed during previous surgery remain metastatic and may also be candidates for PROVENGE2,5

Give patients like Mike the potential overall survival advantage of PROVENGE immunotherapy

  • Median overall survival in clinical trials was 25.8 months with PROVENGE (n=341) vs 21.7 months with control (n=171); P=0.032 (95% CI: 0.614, 0.979)

Findings from a 2012 clinical trial. Data represent screen failures of patients trying to enroll in the Phase 3 study comparing zibotentan with placebo. Of the 2577 patients, 818 who were presumed to have nonmetastatic CRPC actually had metastatic disease and did not qualify for the study.2

Mike’s story*: early treatment with PROVENGE immunotherapy may help extend his life

  • PROVENGE was initiated early — when Mike had a low tumor burden
  • PROVENGE treatment was completed in about a month
  • Mike’s immune system was then activated for a sustained immune response
  • Median overall survival in clinical trials was 25.8 months with PROVENGE (n=341) vs 21.7 months with control (n=171); P=0.032 (95% CI: 0.614, 0.979)

Mike represents one of the 87% of newly diagnosed mCRPC patients who may be eligible for early treatment with PROVENGE to fight his metastatic castrate-resistant prostate cancer1

*Not an actual patient.
A sustained immune response was seen out to 26 weeks in the pivotal study (the last time point measured). No conclusions could be made regarding the clinical significance of the observed immune responses.1